Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022;20(5):373-379.
doi: 10.2174/1570162X20666220805103411.

Effectors of Hyperlipidemia Among Patients with HIV/AIDS Taking Second-line Antiretroviral Therapy Based on Registry Data

Chunling Yang  1 , Dongli Wang  1 , Yanmin Ma  2 , Zhibin Liu  1   3 , Huijun Guo  3 , Feng Sang  4 , Qianlei Xu  1   3 , Yantao Jin  3
Affiliations

Effectors of Hyperlipidemia Among Patients with HIV/AIDS Taking Second-line Antiretroviral Therapy Based on Registry Data

Chunling Yang et al. Curr HIV Res. 2022.

Abstract

Objective: In this study, we aimed to determine the prevalence and effectors of hyperlipidemia among People Living with HIV/AIDS (PLWHA) and taking second-line Antiretroviral Therapy (ART) using registry data in central China.

Methods: We conducted a cross-sectional study and collected information of PLWHA on secondline ART during 2018 from two medical registries. Hyperlipidemia was defined according to the 2016 Chinese guidelines for the management of dyslipidemia in adults. Univariate and multivariate logistic regression analyses were performed to explore the influencing factors of hyperlipidemia. We calculated Odds Ratios (ORs) and 95% Confidence Intervals (CIs).

Results: A total of 2886 PLWHA taking second-line ART were included in this study, and 978 (33.9%) had hyperlipidemia. Female patients, those with hyperglycemia, and patients with CD4+ cell counts >500 cells/μL had a higher prevalence of hyperlipidemia with 37.0%, 49.0%, and 41.3%, respectively. Multivariate analysis showed that CD4+ cell count 350-500 cells/μL (OR = 1.72, 95% CI: 1.26-2.38), CD4+ cell count >500 cells/μL (OR = 2.49, 95% CI: 1.85-3.38), and FPG >6.2 mmol/L (OR = 2.08, 95% CI:1.64-2.65) were risk factors for hyperlipidemia. Male sex (OR = 0.72, 95% CI: 0.61-0.85) and Hb <110 g/L (OR = 0.59, 95% CI: 0.45-0.76) were protective factors against hyperlipidemia.

Conclusion: PLWHA on second-line ART had a higher prevalence of hyperlipidemia. Gender, CD4+ cell count, FPG, and hemoglobin were influencing factors of hyperlipidemia.

Keywords: AIDS; HIV; cross-sectional study; hyperlipidemia; mortality.; second-line ART.

PubMed Disclaimer

References

    1. Global HIV statistics fact sheet. Online, 2020-12-1, cited 2020-2-21. 2020;1(1):198. https://www.unaids.org/sites/default/files/media_asset/UNAIDS_FactSheet_...
    1. McGettrick P., Mallon P.W.G., Sabin C.A. Cardiovascular disease in HIV patients: Recent advances in predicting and managing risk. Expert Rev. Anti Infect. Ther. 2020;18(7):677–688. doi: 10.1080/14787210.2020.1757430. - DOI - PubMed
    1. Tran B.X., Vu G.T., Ha G.H., et al. Global mapping of interventions to improve the quality of life of people living with HIV/AIDS: Implications for priority settings. AIDS Rev. 2020;23(3):91–102. - PubMed
    1. Martínez E., Milinkovic A., Buira E., et al. Incidence and causes of death in HIV-infected persons receiving highly active antiretroviral therapy compared with estimates for the general population of similar age and from the same geographical area. HIV Med. 2007;8(4):251–258. doi: 10.1111/j.1468-1293.2007.00468.x. - DOI - PubMed
    1. Causes of death in HIV-1-infected patients treated with antiretroviral therapy, 1996-2006: Collaborative analysis of 13 HIV cohort studies. Clin. Infect. Dis. 2010;50(10):1387–1396. doi: 10.1086/652283. - DOI - PMC - PubMed

Publication types